Neuvivo Raises $11 Million to Develop Treatment for ALS

Rare Daily Staff

Neuvivo, a late-clinical stage biopharmaceutical company, said it raised $11 million to advance development of a treatment for amyotrophic lateral sclerosis.

Amyotrophic lateral sclerosis (ALS) is a progressive and fatal neurodegenerative disorder caused by motor neuron death in the brain and spinal cord. Motor neuron loss in ALS leads to deteriorating muscle function, the inability to move and speak, respiratory paralysis, and eventually, death. More than 90 percent of people with ALS have sporadic disease, showing no clear family history. ALS affects approximately 29,000 people in the United States.

Neuvivo’s lead candidate NP001 has shown promise to be effective in a large subset of people living with ALS, coupled with an excellent safety profile.

PrimeStreet Capital led the financing and General Partner Virit Vichitvadakan will join the company’s Board of Directors.